Also Maraviroc and BMS-813160:

BMS-813160 overview:

BMS-813160 is under development for solid tumor, metastatic colorectal cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, gastric cancer, renal cell carcinoma and hepatocellular carcinoma. It is administered orally as a capsule. The drug candidate is a dual CCR2/CCR5 antagonist.
_______

So our trial results will eventually also be compared to Maraviroc & Bristol Meyers Squibb

Let's get it Leronlimab!!